# Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD

> **NCT03803124** · PHASE3 · COMPLETED · sponsor: **Regional Hospital Holstebro** · enrollment: 20 (actual)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03803124
- **Lead sponsor:** Regional Hospital Holstebro
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-12-15
- **Final completion:** 2017-12-15
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803124, "Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03803124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*